DSM Reports Steady Growth, Seeks Deal in Pharmaceuticals
08:49 AM | August 2, 2011 | Alex Scott
DSM has reported Ebitda for the second quarter of the year up 2% to €339 million ($482 million) on sales up 7% to €2.3 billion. Strong life sciences results were driven by robust growth in the group’s...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.